OBJECTIVE: Internal tandem duplication (ITD) mutations of the FLT3 receptor are associated with a high incidence of relapse in acute myeloid leukemia (AML). Expression of the CXCR4 receptor in FLT3-ITD-positive AML is correlated with poor outcome, and inhibition of CXCR4 was shown to sensitize AML blasts toward chemotherapy. The aim of this study was to evaluate the impact of FLT3-ITD on cell proliferation and CXCR4-dependent migration in human hematopoietic progenitor cells and to investigate their response to CXCR4 inhibition. MATERIALS AND METHODS: We used primary blasts from patients with FLT3-ITD or FLT3 wild-type AML. In addition, human CD34(+) hematopoietic progenitor cells were transduced to >70% with retroviral vectors containing human FLT3-ITD. RESULTS: We found that FLT3-ITD transgene overexpressing human hematopoietic progenitor cells show strongly reduced migration toward stromal-derived factor-1 in vitro and display significantly reduced bone marrow homing in nonobese diabetic severe combined immunodeficient mice. Cocultivation of FLT3-ITD-positive AML blasts or hematopoietic progenitor cells on bone marrow stromal cells resulted in a strong proliferation advantage and increased early cobblestone area-forming cells compared to FLT3-wild-type AML blasts. Addition of the CXCR4 inhibitor AMD3100 to the coculture significantly reduced both cobblestone area-forming cells and proliferation of FLT3-ITD-positive cells, but did not affect FLT3-wild-type cells-highlighting the critical interaction between CXCR4 and FLT3-ITD. CONCLUSION: CXCR4 inhibition to decrease cell proliferation and to control the leukemic burden may provide a novel therapeutic strategy in patients with advanced FLT3-ITD-positive AML. Copyright 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
OBJECTIVE: Internal tandem duplication (ITD) mutations of the FLT3 receptor are associated with a high incidence of relapse in acute myeloid leukemia (AML). Expression of the CXCR4 receptor in FLT3-ITD-positive AML is correlated with poor outcome, and inhibition of CXCR4 was shown to sensitize AML blasts toward chemotherapy. The aim of this study was to evaluate the impact of FLT3-ITD on cell proliferation and CXCR4-dependent migration in human hematopoietic progenitor cells and to investigate their response to CXCR4 inhibition. MATERIALS AND METHODS: We used primary blasts from patients with FLT3-ITD or FLT3 wild-type AML. In addition, humanCD34(+) hematopoietic progenitor cells were transduced to >70% with retroviral vectors containing humanFLT3-ITD. RESULTS: We found that FLT3-ITD transgene overexpressing human hematopoietic progenitor cells show strongly reduced migration toward stromal-derived factor-1 in vitro and display significantly reduced bone marrow homing in nonobese diabetic severe combined immunodeficientmice. Cocultivation of FLT3-ITD-positive AML blasts or hematopoietic progenitor cells on bone marrow stromal cells resulted in a strong proliferation advantage and increased early cobblestone area-forming cells compared to FLT3-wild-type AML blasts. Addition of the CXCR4 inhibitor AMD3100 to the coculture significantly reduced both cobblestone area-forming cells and proliferation of FLT3-ITD-positive cells, but did not affect FLT3-wild-type cells-highlighting the critical interaction between CXCR4 and FLT3-ITD. CONCLUSION:CXCR4 inhibition to decrease cell proliferation and to control the leukemic burden may provide a novel therapeutic strategy in patients with advanced FLT3-ITD-positive AML. Copyright 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
Authors: Oscar M Pello; María del Carmen Moreno-Ortiz; José Miguel Rodríguez-Frade; Laura Martínez-Muñoz; Daniel Lucas; Lucio Gómez; Pilar Lucas; Enrique Samper; Miguel Aracil; Carlos Martínez; Antonio Bernad; Mario Mellado Journal: Blood Date: 2006-08-15 Impact factor: 22.113
Authors: H Kiyoi; T Naoe; Y Nakano; S Yokota; S Minami; S Miyawaki; N Asou; K Kuriyama; I Jinnai; C Shimazaki; H Akiyama; K Saito; H Oh; T Motoji; E Omoto; H Saito; R Ohno; R Ueda Journal: Blood Date: 1999-05-01 Impact factor: 22.113
Authors: Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer Journal: Blood Date: 2002-06-15 Impact factor: 22.113
Authors: Bruno Nervi; Pablo Ramirez; Michael P Rettig; Geoffrey L Uy; Matthew S Holt; Julie K Ritchey; Julie L Prior; David Piwnica-Worms; Gary Bridger; Timothy J Ley; John F DiPersio Journal: Blood Date: 2008-12-02 Impact factor: 22.113
Authors: Benjamin H Lee; Zuzana Tothova; Ross L Levine; Kristina Anderson; Natalija Buza-Vidas; Dana E Cullen; Elizabeth P McDowell; Jennifer Adelsperger; Stefan Fröhling; Brian J P Huntly; Miloslav Beran; Sten Eirik Jacobsen; D Gary Gilliland Journal: Cancer Cell Date: 2007-10 Impact factor: 31.743
Authors: Silvia F Soriano; Patricia Hernanz-Falcón; José Miguel Rodríguez-Frade; Ana Martín De Ana; Ruth Garzón; Carla Carvalho-Pinto; Antonio J Vila-Coro; Angel Zaballos; Dimitrios Balomenos; Carlos Martínez-A; Mario Mellado Journal: J Exp Med Date: 2002-08-05 Impact factor: 14.307
Authors: Edward Allan R Sison; Rachel E Rau; Emily McIntyre; Li Li; Donald Small; Patrick Brown Journal: Br J Haematol Date: 2013-01-07 Impact factor: 6.998
Authors: Kirsten M Williams; Amber R Moore; Philip J Lucas; Juin Wang; Catherine V Bare; Ronald E Gress Journal: Exp Hematol Date: 2017-05-26 Impact factor: 3.084
Authors: Dominik Schnerch; Jasmin Yalcintepe; Andrea Schmidts; Heiko Becker; Marie Follo; Monika Engelhardt; Ralph Wäsch Journal: Am J Cancer Res Date: 2012-08-20 Impact factor: 6.166
Authors: E Weisberg; A K Azab; P W Manley; A L Kung; A L Christie; R Bronson; I M Ghobrial; J D Griffin Journal: Leukemia Date: 2011-12-20 Impact factor: 11.528
Authors: Edward Allan R Sison; Daniel Magoon; Li Li; Colleen E Annesley; Rachel E Rau; Donald Small; Patrick Brown Journal: Oncotarget Date: 2014-10-15